GABARAP and neoplasm: We found that inhibition of tumour-secreted ImpL2 (RasV12dlg1RNAi), was sufficient to reduce ATG8a levels by 7 days AEL (Fig. EV3W–Y), and Mhc levels by 5 days AEL (Fig. EV3Z–BB), confirming that muscle perturbations are driven by tumour-secreted ImpL2.